Methods of treating an eye disorder

A method of treating retinal vein occlusion (RVO), comprising:

• administering intravitreally two loading doses of an anti-VEGF antibody conjugate to a subject in need of treating RVO, wherein the two loading doses are administered about one month apart, wherein about 5 mg of antibody per loading dose is administered to the subject in the form of the anti-VEGF antibody conjugate;
• and
• administering intravitreally one or more subsequent doses of the anti-VEGF antibody conjugate to the subject after the second loading dose at a dosing schedule of Q8W, wherein about 5 mg of antibody per subsequent dose is administered to the subject in the form of the anti-VEGF antibody conjugate, thereby treating RVO, wherein the anti-VEGF antibody conjugate comprises:
• an anti-VEGF-A antibody comprising a light chain and a heavy chain, wherein the heavy chain comprises CDRH1:
• GYDFTHYGMN (SEQ ID NO:
• 9), CDRH2:
• WINTYTGEPTYAADFKR (SEQ ID NO:
• 10), and CDRH3:
• YPYYYGTSHWYFDV (SEQ ID NO:
• 11), and the light chain comprises CDRL1:
• SASQDISNYLN (SEQ ID NO:
• 12), CDRL2:
• FTSSLHS (SEQ ID NO:
• 13), and CDRL3:
• QQYSTVPWT (SEQ ID NO:
• 14);
• and
• a phosphorylcholine-containing polymer covalently bonded to the heavy chain, and
• wherein the anti-VEGF antibody conjugate has the following structure:
• wherein:
• each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L;
• the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C443(EU numbering), which bond is depicted on one of the heavy chains;
• PC is
• where the curvy line indicates the point of attachment to the rest of the polymer, where X is a)—OR where R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl, or —I, d) —SCN, or e) —NCS;
• and
• n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

A method of treating retinal vein occlusion (RVO), comprising:

• administering intravitreally two loading doses of an anti-VEGF antibody conjugate to a subject in need of treating RVO, wherein the two loading doses are administered about one month apart, wherein about 5 mg of antibody per loading dose is administered to the subject in the form of the anti-VEGF antibody conjugate;
• and
• administering intravitreally one or more subsequent doses of the anti-VEGF antibody conjugate to the subject after the second loading dose at a dosing schedule of Q8W, wherein about 5 mg of antibody per subsequent dose is administered to the subject in the form of the anti-VEGF antibody conjugate, thereby treating RVO,
• wherein the anti-VEGF antibody conjugate comprises:
• an anti-VEGF-A antibody comprising a light chain and a heavy chain, wherein the sequence of the anti-VEGF-A antibody heavy chain is SEQ ID NO:
• 1,with or without the C-terminal lysine, and the sequence of the anti-VEGF-A antibody light chain is SEQ ID NO. 2;
• and
• a phosphorylcholine-containing polymer covalently bonded to the heavy chain, and
• wherein the anti-VEGF antibody conjugate has the following structure:
• wherein:
• each heavy chain of the anti-VEGF-A antibody is denoted by the letter H, and each light chain of the anti-VEGF-A antibody is denoted by the letter L;
• the polymer is bonded to the anti-VEGF-A antibody through the sulfhydryl of C443 (EU numbering), which bond is depicted on one of the heavy chains;
• PC
• is where the curvy line indicates the point of attachment to the rest of the polymer, where X is a) —OR where R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl, or —I, d) —SCN, or e) —NCS;
• and
• n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.